SCHEMBL6483189

SCHEMBL6483189

Cc1cccc(C)c1N1CCN(CCCN2C(=O)C3CC=CCC3C2=O)CC1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 4/20 0.56
HTR1A P08908 4/20 0.55
DRD2 P14416 3/20 0.55
HTR2A P28223 3/20 0.55
SLC6A2 P23975 2/20 0.52
SLC6A4 P31645 1/20 0.52
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 1/20 0.43
SLC6A3 Q01959 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7102140 0.99 HTR7 (0.55) HTR7HTR1ADRD2HTR2ASLC6A2
SCHEMBL6474505 0.86 DRD2 (0.60) HTR7HTR1ADRD2HTR2ANPC1
Hydrochloric Acid SCHEMBL7615470 0.85 DRD2 (0.59) HTR7HTR1ADRD2HTR2ANPC1
SCHEMBL6475395 0.81 HTR1A (0.67) HTR7HTR1ADRD2HTR2AALDH1A1
SCHEMBL6474033 0.81 HTR7 (0.60) HTR7HTR1ADRD2HTR2AMEN1
SCHEMBL6474802 0.80 DRD2 (0.49) HTR7HTR1ADRD2HTR2AMEN1
Hydrochloric Acid SCHEMBL7610245 0.80 HTR7 (0.59) HTR7HTR1ADRD2HTR2AMEN1
Hydrochloric Acid SCHEMBL7606820 0.80 HTR1A (0.65) HTR7HTR1ADRD2HTR2AALDH1A1
Hydrochloric Acid SCHEMBL7098285 0.79 HTR7 (0.48) HTR7HTR1ADRD2HTR2AMEN1
SCHEMBL6481286 0.79 DRD2 (0.60) HTR7HTR1ADRD2HTR2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6914064-B2 1,4-Disubstituted piperazine derivatives useful as uro-selective α1-adrenoceptor blockers RANBAXY LABORATORIES LIMITED (IN) 2005-07-05 US claimed
US-20020156085-A1 1,4-Disubstituted piperazine derivatives useful as uro-selective alpha1-adrenoceptor blockers RANBAXY LABORATORIES LIMITED (IN) 2002-10-24 US claimed
US-6914064-B2 1,4-Disubstituted piperazine derivatives useful as uro-selective α1-adrenoceptor blockers RANBAXY LABORATORIES LIMITED (IN) 2005-07-05 US disclosed
US-20020156085-A1 1,4-Disubstituted piperazine derivatives useful as uro-selective alpha1-adrenoceptor blockers RANBAXY LABORATORIES LIMITED (IN) 2002-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156085-A1 1,4-Disubstituted piperazine derivatives useful as uro-selective alpha1-adrenoceptor blockers ADRB1, ADRB2, ADRA1B HTR7 426/4885HTR1A 120/4885DRD2 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.